Abstract
The non-selective NMDA-receptor blockers ketamine and esketamine have been demonstrated efficacy in multiple clinical trials in patients with major depressive disorder (MDD). The use of those substances is limited due to high probability of psychotomimetic-like effects. The NR2B subunit is considered key in mediating the efficacy of ketamine. BI 1569912 is a novel negative allosteric modulator of NR2B-containing NMDA receptors under development for the treatment of MDD.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
